Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Neutrophil granulocyte markers may distinguish between demyelinating diseases

Publish date:: October 21, 2020

Key clinical point: Neutrophil granulocyte markers have high sensitivity and specificity for distinguishing acute NMOSD and MOGAD from relapsing-remitting MS.

Major finding: The area under the curve was 0.91 for elastase and neutrophil gelatinase-associated lipocalin, 0.82 for myeloperoxidase, and 0.81 for matrix metalloproteinase-8.

Study details: An evaluation of CSF from 42 patients with NMOSD, 6 with MOGAD, 41 with relapsing-remitting MS, and 25 healthy controls.

Disclosures: Dr. Leppert did not report any disclosures or outside funding. Dr. Weinshenker holds a patent on a diagnostic test for NMOSD and has received compensation for activities related to clinical trials in NMOSD.

Citation:

Leppert D et al. MSVirtual2020. Abstract LB01.03.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,